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Abstract  
 Background: This study sought to explore the increase of usage of 
low molecular weight heparins (LMWH), for venous thromboembolism 
(VTE) treatment and prophylaxis during the period of pregnancy. Materials 
and methods: A retrospective study was undertaken during 01 January – 31 
June of 2013, in the Department of Gynecology and Obstetrics, at Clinical 
Hospital in Tetova. Data were collected for the following: patient 
demographics, week and month of pregnancy, number of pregnancies for 
each patient, diagnosis, drug details and the cost for the entire period of 
hospitalization. Results: Over six months, the total number of pregnant 
women was 1020, from that number, 366 (35.88 %) were prescribed 
LMWH. Majority of patients given LMWH were aged 25-30, 196 (53.55 %). 
Clexane 2000 UI and Fraxiparine 0.4UI, were the most prescribed 
anticoagulant, 98 (26.78 %), respectly 97 (26.50 %) of patients received this 
therapy. The most common diagnosis that was foud in the study was 
nonpathologycal pregnancy asocciated with high levels of D-dimers  177 
(48.36 %) patients.  Conclusions: The results of this study indicate that there 
is an urgent need to improve the prescription of anticoagulants in the 
Department of Gynecology and Obstetrics, Clinical Hospital of Tetova, 
Republic of Macedonia.  
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Introduction 
  Anticoagulant treatment for deep-vein thrombosis aims to prevent 
pulmonary embolism and recurrent thrombosis and also to avoid excessive 
bleeding. In addition, both the effect of therapy on the patients' well-being 
and the cost of therapy are factors to be weighed in determining the optimal 
treatment. It is current practice to treat acute venous thrombosis with 
intravenous standard (unfractionated) heparin for at least five days in a dose 
adjusted to lengthen the activated partial-thromboplastin time into a desired 
range (Koopman M, et al, 1996). LMWHs are effective and indicated for the 
prevention of venous thromboembolism, for the treatment of venous 
thrombosis, for the treatment of patients with unstable angina ( Jack H, et al, 
2001), LMWH do not cross the placenta (Dimitrakakis C, et al, 2000)(Omri 
A, et al, 1989)(Robin F, et al 1999) and have several clinical advantages over 
un-fractionated heparin. Their bioavailability is better, with a half life two to 
four times longer than un-fractionated heparin.The biological monitoring is 
reduced, and LMWH are easier to use with one or two daily injections, a 
feature that is particularly attractive to physicians and patients (Philippe D, et 
al, 2007). 
 Women with a history of VTE (with or without thrombophilia) are 
believed to have a higher risk of recurrence in subsequent pregnancies 
(Ginsberg J, et al, 2001). Estimates of the rate of recurrent venous 
thrombosis during pregnancy in women with a history of VTE have varied 
between zero and 13% (De Swieet M, et al, 1987)(Tengborn L, et al 
1989)(Ginsberg J, et al, 2001). Treatment of VTE with LMWH has come of 
age. A large body of data for several of these products has been provided by 
well-designed clinical trials that featured clinically relevant end points. 
Estimates of treatment effect are available with acceptable confidence 
intervals. Treatment effects appear generalize, i.e., they apply to large 
populations of patients with VTE (10Carman, et al, 1999). Althought the 
prevalence of clinically significant maternal heart disease during pregnancy 
is low (probably less than 1 percent) (Siu SC, et al, 2001), its presence 
increases the risk of adverse maternal, fetal and neonatal outcomes (Siu SC, 
et al, 2002). The aim of this study was to describe the consumption of 
anticoagulants, respectively low molecular weight heparins along pregnancy, 
in the Department of Gynecology and Obstetrics, at  Clinical Hospital in 
Tetova. 
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Material and Methods 
Study design 
 We collected data on low molecular weight heparins prescription, 
from the Hospital Archive during the period of six months from 1st January 
to 31st June 2013. Data were collected retrospectively from medical record 
of eligible patients. The collection started in October and finished in 
December 2013. 
 
Data collection procedure 
 Data were collected for the following: patient demographics, week 
and month of pregnancy, number of pregnancies for each patient, duration of 
hospital stay, clinical and laboratory investigations, diagnosis, drug details; 
which include the name of the drug, dosage form, dose frequency, total cost 
of the drug, the amount of each given ampoule application and the cost for 
the entire period of hospitalization. 
 
Results 
Patient’s demographic characteristics 
 Among the total number of 1020 pregnant women, 366 (35.88%) 
were prescribed low molecular weight heparins. The age range of pregnant 
women who visited the Department of Gynecology and Obstetrics was 
between 18 and 49 and the group with the highest attendance was 25 – 35: 
196 (53.55 %) patients. The risk of adverse fetal outcomes was also 
substantially greater among women older than 35 years of age or younger 
than 20 years of age than among women between these ages with similar risk 
factors. Indexes of risk derived from and validated in this population may be 
used in the counseling of women before conception (13Reimold Sh, et al 
2003).  101 (27.60 %) of the patients were from Tetova and the urban places 
around and the biggest number, 265 (72.40 %) patients, came from rural 
parts (villages) around Tetova and Gostivar. Patients’ characteristics are 
summarized in Table 1. 
Table 1. Patient’s demographic characteristics. 
Age Total frequency (N) 
Percent 
(%) 
18-20 2 0.55 
21-24 46 12.57 
25-30 196 53.55 
31-35 79 21.58 
>35 43 11.75 
Living place Total frequency (N) 
Percent 
(%) 
Urban 101 27.60 
Rural 265 72.40 
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Ordinal number and the months of pregnancy 
 For 231 women (63.11 %) this was their firs pregnancy, 68 (18.57 %) 
declared that this is their second, followed by 67 (18.31 %) for which this 
was their third, fourth or fifth pregnancy. The earliest stage of using LMWH 
was the second month of pregnancy, 5 (1.37 %) pregnant women received 
anticoagulant therapy over that month. The most common patients were 
women in the ninth month 125 (34.15 %), followed by them in the last 
month of pregnancy 82 (22.40 %). The detailed explanation about months of 
pregnancy is given in the Figure 1. 
Figure 1. Number of patients in each month of pregnancy 
 
 
Percentage share on usage of different classes of LMWH  
 The biggest percentage of patients, 26.78 % received Clexane 
(enoxaparin) 4000 IU anti- Factor XA in 0.4ml, followed by them with 
Fraxiparine (nadroparin calcium) 2850 IU anti-Factor XA in 0.3 ml, 26.50 
%. 25.96 % of patients was prescribed Fraxiparine (nadroparin calcium) 
3800 IU anti-Factor XA in 0.4 ml and Clexane (enoxaparin) 2000 IU anti-
Factor XA in 0.2 ml received 20.22 %. Fragmine (dalteparin sodium) 5000 
IU anti-Factor XA in 1 ml was the less anticoagulant prescribed, 0.54%.   
 
Frequency of Diagnosis 
 The most common diagnosis that was foud in the study was 
nonpathologycal pregnancy, asocciated with high levels of D-dimers 177 
(48.36 %).76 patients (20.76 %) were diagnosed hypercoagulable, 62 (16.93 
% ) had risky pregnancies and 9 (2.5 %) of them were carying twins. 42  
5 0 2 
12 
23 
37 
80 
125 
82 
0
20
40
60
80
100
120
140
Month
II
Month
III
Month
IV
Month
V
Month
VI
Month
VII
Month
VIII
Month
IX
Month
X
N
um
be
r o
f p
at
ie
nt
s 
Pregnancy month 
European Scientific Journal October 2015 edition vol.11, No.30 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
 
83 
(11.45 %) patients had other diagnosis: pregnancy after IVF, pregnancy 
associated with diabetes mellitus, pregnancy associated with low levels of 
albumines and pregnancy after some miscarriages were among them (Table 
2, Figure 2). 
Table 2. Frequency of diagnosis 
Diagnosis 
ID Type of diagnosis 
Total 
frequency 
(N) 
Percent 
(%) 
D1 Nonpathologycal pregnancy 177 48.36% 
D2 Hyperthrombotical pregnancy 76 20.76% 
D3 Risky pregnancies 62 16.93% 
D4 Pregnancy with twins 9 2.5% 
D5 Pregnancy afer some miscarriages 6 1.64% 
D6 Gestosis pregnancy 6 1.64% 
D7 Hypothrombotical pregnancy + hypoalbuminemia 6 1.64% 
D8 Pregnancy afer IVF 5 1.36% 
D9 EPH gestosis pregnancy 5 1.36% 
D10 Pregnancy associated with hypoalbuminemia 2 0.55% 
D11 Varices cruris pregnancy (Pregnant women with varicose veins) 2 0.55% 
D12 Eph gestosis pregnancy + hypoalbuminemia 2 0.55% 
D13 Pregnancy after FM In utero 1 0.27% 
D14 SGA Pregnancy (small for gestational age) 1 0.27% 
D15 Varices Valvulae pregnancy 1 0.27% 
D16 Hyperthrombotical pregnancy + hypotensio 1 0.27% 
D17 Risky pregnancy + Diabetes Mellitus 1 0.27% 
D18 Hyperthrombotical + E gestosis pregnancy 1 0.27% 
D19 Pregnancy after abruption of placenta 1 0.27% 
D20 Pregnancy + fracturae tibia 1 0.27% 
 
 Compared with a year earlier, the number of patients with heparin 
treated with low molecular mass (low molecular weight heparin) is growing. 
From 1 January to 31 December 2012, the total number of pregnancy, 1447, 
298 (20.60 %) of them were treated with anticoagulants. 
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Figure 2.  Frequency of diagnosis 
 
 
Discussion 
 To our knowledge, this is one of the first studies to investigate the 
prescription of anticoagulants in this hospital. Compared with a year earlier, 
the number of patients treated with low molecular weight heparins is 
growing. From 1 January to 31 December 2012 the total number of 
pregnancy, 1447, 298 (20.60 %) of them were traded with anticoagulants. In 
the period of 1 January to 30 June 2013, this number marks the doubling of 
cases. While for the entire year 2012, the number of patients treated was 298, 
only for the first six months of 2013, the number of patients was 366 (35.88 
% respectively of the total number of pregnancy, which was in 1020)  
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 For as much as they are safe for the baby, because they do not allow 
passing placental barrier, this therapy is being used increasingly. However, 
in our hospital, this number is too high, compared with other countries, thing 
which requires a detailed study about prescribing these medicines. 
 In pregnancy, however, long-term administration of heparin or 
LMWH is preferred to prevent systemic embolism in women with medical 
mechanical heart valves, and to prevent fetal loss in women with 
antiphospholipid antibodies. In all these instances the long-term use of 
heparin or LMWH carries a risk of osteoporosis ( Griffith Sh, et al, 
1965)(Monreal M, et al, 1994)(Jack H, et al 2001). 
 Significant reductions in bone density have been reported in about 30 
% of patients, and symptomatic vertebral fractures occur in 2 to 3 % of 
patients receiving heparin for 1 month or more (Dahlman TC.1993)(Jack H, 
et al 2001). 
 The current American College of Chest Physicians guidelines 
recommend testing of women with adverse pregnancy outcomes (recurrent 
pregnancy loss, prior sever or recurrent preeclampsia, abruptions, or 
otherwise unexplained intrauterine death) for congenital thrombophilias  and 
antiphospholipid antibodies, and offering treatment to such women, if 
thrombophilic with low-dose aspirin plus prophylactic heparin ( 
unfractionated or LMWH) (Bates SM, et al 2004). 
 
Limitations 
 Even though our study was not prospective and randomized, we have 
made control of all documents included in the medical chart for each patient 
individually. However there are cases when patients repeated, e.g. a pregnant 
woman receives therapy from the beginning of pregnancy until the end of it. 
And in our analysis, identified as a different patient, each time it is presented 
to the hospital to receive anticoagulants.  
 Despite this limitation this study has identified significant increase of 
prescribing these drugs, resulting in an irrational use of anticoagulants during 
pregnancy in Tetova, the Republic of Macedonia. 
 
Conclusion 
 Indeed the benefits from the use of LMWH cross the undesirable side 
effects. Even though the prices are quite high used during the period of 
pregnancy. Careful management, however, is necessary for women treated 
with heparins. The results of this study indicate there is an urgent need to 
improve the prescription of anticoagulants in the Department of Gynecology 
and Obstetrics, Clinical Hospital of Tetova, Republic of Macedonia. 
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